Moderna and Merck announced that their experimental mRNA cancer vaccine, combined with Merck's drug Keytruda, met its trial goals by helping prevent melanoma from returning. The news sent Moderna's stock up sharply, with reports ranging from about 120 percent to as much as 177 percent, while Merck's shares rose around 11 to 13 percent on Wednesday. The results have not yet been peer-reviewed or published, and Moderna's chief executive said the company now sees itself as an oncology company.
NBC News frames the story around scientific promise and caution, emphasizing that results are not yet peer-reviewed, detailing trial mechanics and expert commentary, and noting the Trump administration's cuts to mRNA funding and RFK Jr.'s criticism of the technology as context for uncertainty around the field's future.
Axios and Scientific American frame the trial results as a scientific and market breakthrough, with Axios emphasizing Moderna's stock rebound and political backlash from the Trump administration's mRNA funding cuts, while Scientific American and BBC focus more heavily on the clinical/scientific context, survival statistics, and caveats that data are unpublished and unreviewed.
The Daily Wire and Washington Times frame the story primarily as a market and business event, detailing stock surges, executive quotes about becoming an oncology company, and financial context (Keytruda patent cliff, COVID revenue decline), with minimal or no mention of political controversy over mRNA funding cuts.